On 9 November, a woman with advanced high-grade serous ovarian cancer received an injection no patient had received before. The dose was CryptiVax-1001, Epitopea’s mRNA cancer vaccine, given as maintenance therapy after surgery and first-line platinum chemotherapy. She was the first patient in OVACT, the company’s Phase 1/1b trial.
Epitopea says the study will enrol up to 30 women across up to 10 UK sites. The ClinicalTrials.gov record lists an estimated enrolment of 50, which covers the dose-escalation stage plus an optional expansion. Five dose levels are planned, with dose-limiting toxicity checked over the first 21 days.
HGSOC is the most common and aggressive subtype of ovarian cancer. Around 80% of patients present with advanced or metastatic disease, and nearly all relapse after first-line platinum chemotherapy. Maintenance options work in about half of the ovarian cancer population, which leaves the HRP-positive, BRCA-wildtype group with little that is matched to their tumour biology.
Phase 1/1b, open-label, non-randomised. Dose escalation plus optional expansion.
Population: FIGO stage III–IV HGSOC, HRP+/BRCA-wildtype, after debulking surgery and first-line platinum.
Sites: up to 10 in the UK, from Cambridge and London to Glasgow, Leeds, Leicester and Preston.
Estimated primary completion: March 2029. Registry ID: NCT07665515.
What the first dose does not prove
A first-in-human dose is an operations milestone. It shows that the protocol, the supply chain and the site network can put a patient on treatment. It does not show that the vaccine works. The primary endpoints are safety and tolerability: treatment-emergent adverse events and dose-limiting toxicities. Immunogenicity is measured. The trial is not powered to demonstrate a survival or remission benefit.
The calendar matters more than the announcement. The registry’s estimated primary completion is March 2029. Any claim that this vaccine extends remission stays a hypothesis until then.
Ten UK sites for a dose-escalation study of this size is a lot of geography. That is what a narrow eligibility window looks like in practice: HRP-positive, BRCA-wildtype, stage III–IV disease, no prior cancer vaccine or checkpoint inhibitor, and no recurrence after platinum chemotherapy. The patients who fit are the ones existing maintenance options serve least well.
Why dark-genome antigens change the manufacturing question
CryptiVax-1001 targets antigens that Epitopea’s CryptoMap engine identifies in the so-called dark genome, the non-coding regions long treated as noise. The company calls the resulting targets Cryptigens and says they are shared across patients. That sharing is the commercial point. A shared target set can be manufactured as one product for many patients, instead of a bespoke batch per person.
Personalized mRNA cancer vaccines dominate the field’s headlines. Epitopea’s bet is that the off-the-shelf route is the one that scales. We are sceptical of the phrase “off-the-shelf” until the shelf exists at commercial scale. For now it describes a design choice, not a supply chain.
As we wrote in November, the next mRNA race is about where the payload acts, not whether mRNA can work (our look at SRTD’s precision-mRNA seed). Epitopea’s version of that argument is antigen selection: find targets that many tumours present, then let the immune system do the matching.
The milestone is real. The proof is scheduled for 2029.